PI3Kδ抑制剂帕萨利布的2期研究:复发或难治性边缘区淋巴瘤(CITADEL-204)
CITADEL-204是一项2期研究,评估帕萨利布在复发或难治性边缘区淋巴瘤(R/R MZL)患者中的疗效与安全性,患者按既往是否接受BTK抑制剂分为队列1和队列2。每日给药组(DG)的客观缓解率为58.3%(95%CI 46.1-69.8),完全缓解率为4.2%(95%CI 0.9-11.7),中位缓解持续时间12.2个月(95%CI 8.1-17.5),中位无进展生存期16.5个月(95%CI 11.5-20.6)。帕萨利布单药治疗显示出持久缓解和总体可控的安全性。
要点
- 在每日给药组中,客观缓解率为58.3%(95%CI 46.1-69.8),完全缓解率为4.2%(95%CI 0.9-11.7)。
- 中位缓解持续时间为12.2个月(95%CI 8.1-17.5),中位无进展生存期为16.5个月(95%CI 11.5-20.6)。
- 最常见的治疗中出现的不良事件为腹泻(47.0%)、咳嗽(23.0%)和皮疹(18.0%)。
核心结论
- 帕萨利布单药治疗在复发或难治性边缘区淋巴瘤患者中显示出持久缓解和总体可控的安全性。
研究设计与样本
- 2期CITADEL-204研究(NCT03144674,EudraCT 2017-000970-12)评估帕萨利布在既往接受过BTK抑制剂(队列1)或未接受过BTK抑制剂(队列2)的复发或难治性边缘区淋巴瘤患者中的疗效与安全性。
- 患者年龄≥18岁,组织学确诊为复发或难治性边缘区淋巴瘤,既往接受过≥1线全身治疗(包括≥1种抗CD20抗体)。
- 患者接受帕萨利布20 mg每日一次共8周,之后改为20 mg每周一次(每周给药组[WG])或2.5 mg每日一次(每日给药组[DG]);后续评估选择每日给药组。
- 研究主要终点为客观缓解率。
主要发现
- 由于入组慢于预期,队列1关闭,共入组10例患者(每周给药组n=4;每日给药组n=6)。
- 基于队列2的计划期中分析,未跨越无效性边界,入组继续至研究完成;截至数据截止日期2021年1月15日,队列2共入组并治疗100例患者(每周给药组n=28;每日给药组n=72)。
- 在每日给药组中,客观缓解率为58.3%(95%CI 46.1-69.8),完全缓解率为4.2%(95%CI 0.9-11.7);客观缓解率95%CI下限超过方案定义的阈值40%。
- 中位缓解持续时间为12.2个月(95%CI 8.1-17.5),中位无进展生存期为16.5个月(95%CI 11.5-20.6);中位总生存期未达到。
- 在所有患者中,最常见的治疗中出现的不良事件为腹泻(47.0%)、咳嗽(23.0%)和皮疹(18.0%);最常见的≥3级治疗中出现的不良事件包括腹泻(12.0%)、中性粒细胞减少和肺炎(各9.0%)。
局限性
- 由于入组慢于预期,队列1关闭,共入组10例患者(每周给药组n=4;每日给药组n=6)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of parsaclisib in Bruton tyrosine kinase (BTK) inhibitor-experienced (cohort 1) or BTK inhibitor-naive (cohort 2) patients with R/R marginal zone lymphoma (MZL). Patients aged ≥18 years with histologically confirmed R/R MZL, treated with ≥1 prior systemic therapy (including ≥1 anti-CD20 antibody) received parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group [DG]); DG was selected for further assessment. Primary end point of the study was objective response rate (ORR). Owing to slower than expected recruitment, cohort 1 was closed with 10 patients (WG, n = 4; DG, n = 6) enrolled. Based on a planned interim analysis in cohort 2, the futility boundary was not crossed, and enrollment continued to study completion. At data cutoff (15 January 2021), 100 patients were enrolled and treated in cohort 2 (WG, n = 28; DG, n = 72). In the DG, the ORR was 58.3% (95% confidence interval [CI], 46.1-69.8), with a complete response rate of 4.2% (95% CI, 0.9-11.7); the lower bound of the ORR 95% CI exceeded the protocol-defined threshold of 40%. The median duration of response was 12.2 months (95% CI, 8.1-17.5) and progression-free survival was 16.5 months (95% CI, 11.5-20.6); median overall survival was not reached. The most common treatment-emergent adverse events (TEAEs) among all patients were diarrhea (47.0%), cough (23.0%), and rash (18.0%); the most common grade ≥3 TEAEs included diarrhea (12.0%), neutropenia, and pneumonia (9.0% each). TEAEs led to dose interruptions, reductions, and discontinuations in 56.0%, 16.0%, and 29.0% of all patients, respectively. Durable responses and an overall manageable safety profile were demonstrated in patients with R/R MZL treated with parsaclisib monotherapy.
引用
- Phillips TJ, Avigdor A, Gurion R, et al. A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204). Blood Adv. 2024. PMID: 38113459. doi:10.1182/bloodadvances.2023010648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。